Dozens of FDA-approved cancer treatments work through mechanisms entirely different from traditional chemotherapy and external-beam radiation. Surgery, immunotherapy, targeted molecular drugs, hormone-blocking agents, focal ablation, and newer approaches like tumor-treating fields and protein-degrading drugs all fall outside those two categories and are used daily in oncology clinics around the world. Which options apply depends on cancer type, stage, molecular profile, and the individual patient, but the menu of proven non-chemo, non-radiation treatments has expanded dramatically over the past two decades.
Surgery Alone Can Be Curative
The oldest cancer treatment remains one of the most effective. For many solid tumors caught early, surgical removal of the tumor and surrounding tissue is the entire treatment. Certain early-stage skin cancers, thyroid cancers, kidney cancers, and some childhood solid tumors fall into this category. St. Jude Children’s Research Hospital notes that for some solid tumors in children, surgery alone is considered curative and no additional therapy is needed.1St. Jude Children’s Research Hospital. Solid Tumor Treatment Program The same principle applies to adults with localized disease in many organs. The key factor is whether the surgeon can achieve clear margins, meaning no cancer cells are found at the edges of the removed tissue. When they can, no chemo or radiation may be necessary.
Immunotherapy
Immunotherapy works by training or unleashing the patient’s own immune system to recognize and attack cancer cells. Several distinct types exist, and they represent some of the biggest advances in cancer treatment over the past fifteen years.
Checkpoint Inhibitors
Cancer cells often hide from the immune system by exploiting “checkpoint” proteins on the surface of immune cells. These proteins normally prevent the immune system from attacking healthy tissue, but tumors co-opt them to avoid destruction. Drugs called checkpoint inhibitors block these proteins and let immune cells do their job. The FDA has approved three categories: PD-1 inhibitors like nivolumab and pembrolizumab, PD-L1 inhibitors like atezolizumab and durvalumab, and the CTLA-4 inhibitor ipilimumab.2PubMed Central. Immune Checkpoint Inhibitors in Cancer Therapy These drugs have been used successfully in metastatic melanoma, kidney cancer, head and neck cancers, and non-small-cell lung cancer, among others.
Checkpoint inhibitors do have a ceiling, though. They work by amplifying immune activity that already exists; they cannot create tumor-targeting ability from scratch. When a tumor has poor-quality antigens, defective antigen presentation, a suppressive surrounding microenvironment, or deeply exhausted T cells, checkpoint blockade alone may not be enough.3PubMed Central. Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies This explains why response rates vary widely across cancer types. Some patients experience dramatic, long-lasting remissions while others see little benefit.
CAR-T Cell Therapy
CAR-T therapy takes a fundamentally different approach. A patient’s own T cells are removed, genetically engineered in a lab to recognize a specific protein on the surface of their cancer cells, and then infused back. Six CAR-T products are now approved by the FDA for blood cancers, including B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.4PubMed Central. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review In one comparison, CAR-T cells improved four-year overall survival in large B-cell lymphoma patients to about 55%, compared with 46% for standard chemotherapy followed by stem cell transplant. In pediatric leukemia, 48% of patients were alive and relapse-free at three years.4PubMed Central. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
CAR-T therapy has been transformative for certain blood cancers, but significant challenges remain, particularly for solid tumors. Barriers include serious toxicities, the risk of antigen escape (where the cancer stops displaying the target protein), and difficulty getting the engineered cells to physically reach and infiltrate solid tumors.5PubMed Central. CAR-T cell therapy: current limitations and potential strategies
Oncolytic Viruses
A less well-known branch of immunotherapy uses viruses that have been engineered or selected to infect and destroy cancer cells while leaving normal tissue largely alone. These oncolytic viruses do double duty: they kill tumor cells directly and, as those cells break apart, they release signals that wake up the immune system and teach it to recognize the cancer.6PubMed Central. The interplay between oncolytic viruses, Toll-like receptor signaling, and chemotherapy in overcoming tumor immune tolerance In effect, the virus turns a “cold” tumor that the immune system ignores into a “hot” one full of immune-attracting inflammation.7PubMed Central. Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation The best-known example is talimogene laherparepvec (T-VEC), approved for melanoma, though many other oncolytic virus candidates are in clinical trials.
Targeted Molecular Therapies
Where chemotherapy poisons rapidly dividing cells indiscriminately, targeted therapies zero in on specific molecular abnormalities that drive a particular cancer’s growth. This makes them effective in cancers that carry those specific mutations and generally causes fewer side effects than chemo.
Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors, or TKIs, block specific enzymes that cancer cells depend on to grow and spread. They are standard care for several cancers. In non-small-cell lung cancer, EGFR inhibitors and KRAS inhibitors have substantially improved survival for patients whose tumors carry those mutations.8Oncologie. Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer Gastrointestinal stromal tumors (GISTs) are another success story. These tumors are driven by mutations in KIT or PDGFRA receptors, and drugs targeting those receptors, including newer agents like ripretinib and avapritinib, have transformed outcomes.9PubMed. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors For patients with rare EGFR compound mutations in lung cancer, second-generation TKIs like afatinib may be particularly effective.10Holistic Integrative Oncology. Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
PARP Inhibitors
PARP inhibitors exploit a clever concept called synthetic lethality. Cancer cells with mutations in BRCA1 or BRCA2 genes already have one DNA repair pathway broken. PARP inhibitors knock out a second repair pathway, and the combined loss of both is lethal to the cancer cell while sparing normal cells that still have functioning BRCA genes.11PubMed Central. PARP inhibitors: Synthetic lethality in the clinic Four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) have been approved for BRCA-mutated ovarian cancer, breast cancer, or platinum-sensitive recurrent ovarian cancer.12PubMed Central. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Tissue-Agnostic Drugs and Bispecific Antibodies
One of the more exciting developments is a class of drugs approved not for a specific organ’s cancer but for any cancer carrying a specific genetic feature, regardless of where it started. These tissue-agnostic therapies represent a shift from thinking about cancer by location to thinking about it by molecular fingerprint.13PubMed. The evolving landscape of tissue-agnostic therapies in precision oncology Larotrectinib and entrectinib, for example, are approved for any solid tumor with an NTRK gene fusion.
Bispecific T-cell engagers are another targeted approach. These engineered antibody molecules physically bridge a T cell to a cancer cell by binding to both at once, forcing the immune system into close contact with the tumor and triggering a killing response.14PubMed. T-cell-engaging bispecific antibodies in cancer They work independently of whether the T cell would normally recognize the tumor, which gives them a different mechanism from checkpoint inhibitors.15PubMed. Bispecific T-cell engaging antibodies for cancer therapy
Hormone Therapy for Hormone-Driven Cancers
Some cancers, particularly breast and prostate cancers, depend on hormones to grow. Blocking or lowering those hormones can slow or stop the cancer without any chemotherapy. In hormone receptor-positive breast cancer, drugs called selective estrogen receptor modulators (SERMs, like tamoxifen) and aromatase inhibitors (AIs, like letrozole) are mainstays of treatment. A large study found that SERMs reduced breast cancer-specific mortality by about 25% in premenopausal women, while AIs achieved a similar reduction in postmenopausal women. The benefit was strongest in postmenopausal women with a specific molecular subtype, where mortality dropped by roughly 40%.16PubMed Central. Differential Effectiveness of Adjuvant Endocrine Therapy According to Menopausal Status, Body Mass Index, and Molecular Subtype in Hormone Receptor-Positive Breast Cancer Hormone therapy can continue for years after initial treatment and is often the primary long-term strategy for preventing recurrence.
For prostate cancer, androgen deprivation therapy (ADT) works on the same principle, cutting off the testosterone that fuels tumor growth. ADT has been a standard treatment for advanced prostate cancer for decades, using drugs or, less commonly now, surgical removal of the testes.
Focal Ablation Techniques
When surgery is not ideal, several techniques can destroy tumors in place without cutting. High-intensity focused ultrasound (HIFU) uses concentrated ultrasound waves to heat and kill a targeted area of tissue. Cryoablation does the opposite, freezing the tumor. Radiofrequency ablation and microwave ablation use heat generated by electromagnetic energy. All of these are being used for both primary and recurrent solid tumors.17Journal of radiology and nuclear medicine. Using High-Intensity Focused Ultrasound in Clinical Oncology HIFU is particularly attractive because it is completely non-invasive; the energy passes through the skin and is focused on the tumor inside the body.
In prostate cancer, both HIFU and cryoablation have been studied as alternatives for patients who are not good candidates for surgery or radiation.18PubMed. HIFU and cryoablation–non or minimal touch techniques for the treatment of prostate cancer. Is there a role for contrast enhanced ultrasound? These techniques are also used in liver cancer, kidney cancer, and bone metastases. The trade-off is that long-term data are still maturing compared to surgery, and the treatments work best for relatively small, well-defined tumors.19PubMed Central. High intensity focused ultrasound vs. cryotherapy as primary treatment for prostate cancer
Tumor-Treating Fields
Tumor-treating fields (TTFields) are one of the more unusual entries on this list. A portable device delivers low-intensity, alternating electric fields to the region of a tumor through adhesive electrode arrays worn on the skin. These fields interfere with cell division by disrupting the assembly of the structures that pull chromosomes apart during mitosis, leading to abnormal chromosome distribution and cancer cell death.20PubMed Central. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells TTFields also appear to delay DNA repair, inhibit new blood vessel formation in tumors, and limit cancer cell migration.21PubMed Central. Tumor-Treating Fields in Glioblastomas: Past, Present, and Future
TTFields are FDA-approved for glioblastoma, one of the most aggressive brain cancers, and are being studied in mesothelioma and other tumor types. Because they work through a physical mechanism rather than a chemical one, they are in a genuinely different category from both drugs and radiation. The main practical barrier is compliance: the device needs to be worn for most of the day to be effective, which some patients find burdensome.
Epigenetic Drugs
Some cancer treatments target not the DNA sequence itself but the chemical modifications that control which genes are turned on or off. Two main classes are used clinically. HDAC inhibitors block enzymes that keep certain genes silenced, and their ability to inhibit the growth of tumor cells has been demonstrated in lab studies and confirmed by clinical approvals for specific lymphomas and myeloma.22PubMed. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics DNA methyltransferase inhibitors like decitabine and azacitidine work by removing methyl groups that silence tumor-suppressor genes, effectively reactivating the cell’s own defenses against uncontrolled growth.23PubMed Central. DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors These drugs are used primarily in blood cancers like myelodysplastic syndromes and acute myeloid leukemia.
Active Surveillance as a Deliberate Strategy
For certain slow-growing cancers, the best initial treatment may be no treatment at all. Active surveillance means closely monitoring a known cancer with regular imaging and testing, and only intervening if the cancer shows signs of progressing. This is not the same as doing nothing; it is a structured protocol with clear triggers for action.
In low-risk prostate cancer, active surveillance has become a mainstream strategy. A large study found that ten years after diagnosis, 49% of men on active surveillance remained free of both progression and treatment, fewer than 2% developed metastatic disease, and fewer than 1% died of their cancer. Importantly, men who did eventually need treatment because of later progression did not have worse outcomes than if they had been treated immediately.24PubMed Central. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer
Active surveillance is also gaining ground for low-risk papillary thyroid carcinoma. In one trial, over 90% of patients continued on surveillance at last follow-up, with only about 7% crossing over to surgery, most because of tumor growth exceeding a predefined threshold.25JAMA Oncology. Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial For patients with small, slow-growing cancers, surveillance spares them surgical risks and side effects without measurably increasing danger.
Newer Approaches on the Horizon
Several newer strategies are in various stages of development and early clinical use. PROTACs (proteolysis-targeting chimeras) are small molecules designed to latch onto a cancer-driving protein and flag it for destruction by the cell’s own waste-disposal machinery. Unlike traditional drugs that block a protein’s activity, PROTACs eliminate the protein entirely, which may help overcome drug resistance.26PubMed Central. Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons The first PROTAC drug, vepdegestrant, received FDA approval in 2025 for patients with ESR1-mutant advanced breast cancer after standard hormone therapy has failed, establishing targeted protein degradation as a clinically validated approach.27Cancer Discovery. Approval of First PROTAC Opens New Era for Targeted Protein Degradation
The gut microbiome is another active frontier. Researchers have found that the composition of a patient’s gut bacteria can influence how well immunotherapy works, and fecal microbiota transplantation is being explored as a way to shift the microbiome toward a composition that supports better treatment responses. Early work suggests FMT may help enhance immunotherapy responses and improve tolerance to other cancer treatments across several tumor types, including melanoma, colorectal cancer, and liver cancer.28PubMed Central. Application and prospects of fecal microbiota transplantation in cancer therapy This research is still early-stage, but it opens an entirely biological angle on cancer treatment that would have seemed far-fetched twenty years ago.
Side Effects Are Not Zero
It is worth confronting a misconception head-on: “not chemo” does not mean “side-effect free.” Immunotherapy, in particular, can trigger immune-related adverse events where the unleashed immune system attacks healthy organs, causing inflammation in the lungs, liver, colon, skin, or endocrine glands. In some cases these side effects can be severe or even life-threatening. Other concerns include disease reactivation (such as dormant tuberculosis flaring up) and, rarely, tumor hyperprogression, where the cancer actually accelerates after immunotherapy begins.29PubMed Central. The dark side of immunotherapy Targeted therapies have their own side-effect profiles: TKIs can cause skin rashes, diarrhea, and liver problems; PARP inhibitors can cause blood count drops and fatigue. The side effects are generally different from those of chemotherapy, but they are real and need management.
Drug Resistance Remains a Central Challenge
One of the hardest realities in cancer treatment, regardless of the modality, is that tumors can develop resistance. Targeted therapies are especially vulnerable to this because they often depend on a single molecular target. If the cancer acquires a new mutation in or around that target, or activates a parallel growth pathway, the drug can stop working. This is a major contributor to cancer mortality, and understanding resistance mechanisms has become a major area of research aimed at designing more durable combination strategies and next-generation inhibitors.30PubMed Central. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology In practice, this is why many patients cycle through multiple lines of therapy, each one working for a time before resistance emerges.
Why “Alternative Medicine” Is a Different Conversation Entirely
Searching for cancer treatments beyond chemo and radiation is entirely reasonable. Many of the treatments described above are standard of care and backed by strong clinical evidence. But there is a critical line between evidence-based non-chemo treatments and unproven alternative remedies marketed as replacements for conventional treatment. A study published in the Journal of the National Cancer Institute compared patients who used alternative medicine instead of conventional cancer treatment with matched patients who received standard therapy. Across all cancer types, alternative medicine users had roughly two and a half times the risk of death. In breast cancer specifically, the risk was more than five times higher. For colorectal cancer, it was about four and a half times higher.31PubMed. Use of Alternative Medicine for Cancer and Its Impact on Survival
The distinction matters because someone searching for non-chemo cancer treatment might encounter websites promoting herbal remedies, special diets, or energy healing as replacements for proven therapies. Using those approaches alongside evidence-based treatment, known as integrative oncology, may be reasonable when supervised by your oncology team. Using them instead of proven treatment is associated with substantially worse outcomes. The treatments covered in this article are all part of mainstream oncology, developed through clinical trials and subject to regulatory approval. They are not alternatives to medicine; they are medicine that happens to work through mechanisms other than cytotoxic chemotherapy or ionizing radiation.